Drug maker CIPLA hopes that the US “diverse” business will help maintain regional growth. production.
According to CIPLA’s management director and global’s highest executive officer Umang Vohra, US movements do not affect Pep -fur (President Emergency Plan for AIDS relief). According to VOHRA, the company has a large -scale oral agent, about $ about 100 million in the United States, in order to establish two inhalors in the United States. He said he invested. The “diversified diversification” approach over the past three years should maintain US business growth. , 2024.
The US government under Trump is considering funding for overseas programs (including peppers) and pausing funds. Apart from that, the US President indicates that the tariffs containing drugs are high because they seem to strengthen local production.
The United States is a considerable market for some Indian drug manufacturers. This is the second largest market after India, accounting for about 27 % of the revenue during the examination period.
Q3fy25 Show
CIPLA has recorded the best quarterly revenue in the quarter. This was 7073 crawls in Q3FY25, increasing 7 % from the same period of the previous year. In addition, the tax -dwelling profit (PAT) during the review was 1,571 crawl, up 49 % from the previous year.
The company said that the company’s quarterly revenue was 2206 million dollars supported by the traction of differentiated assets, which helped to overcome the shortage of Lanreotides.
CIPLA’s 1 -India business was £ 3,146, an increase of 10 % last year. The company said that the R & D costs were 360 ​​crawls or 5.1 % of sales due to product declaration and development initiatives. He added that it had a pure gold position of 8,947 crawls.
